Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

Infants and young children with atopic dermatitis experienced improvements in signs and symptoms with dupilumab treatment regardless of other type 2 comorbidities, according to a study published ...

Dupilumab provides effective therapy for those who have failed other modalities, but it should not be considered first-line therapy for a number of reasons. First, it is costly.

Dupilumab is an effective and safe treatment option for patients with atopic dermatitis (AD) in real-life settings, including those with malignancy and other medical comorbidities, according to a ...

Serious adverse events remained rare and skin remained largely clear in adolescents treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis (AD) for up to 52 weeks in a phase 3 ...

Median changes from Part A baseline to week 52 in type 2 NES in Part C were –1.94 and –1.97 for patients initiated on placebo who switched to dupilumab at week 24 and those on dupilumab for ...

Dupilumab is undergoing Priority Review by the FDA as an add-on maintenance therapy for adults with uncontrolled COPD and type 2 inflammation, with a target action date of June 27, 2024, according ...

One group got dupilumab, and the other placebo (but they kept using the inhalers). The dupilumab patients had an increased ability to exhale (4) as well as other improvements in lung function. In the ...

Dermatology > General Dermatology Dupilumab Gets First FDA-Approved Indication for Prurigo Nodularis — Significant improvement in itch and nodules at 24 weeks seen in two randomized trials by ...

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. New England Journal of Medicine, 2021; 385 (24): 2230 DOI: 10.1056/NEJMoa2106567 ...

Dupilumab was added as an active comparator in the trial because its efficacy has been shown in this population and it was previously evaluated in a similarly designed proof-of-concept study. 6,7 ...